| Field | Specification |
|---|---|
| Target | |
| Alternative names | Cadherin-2; CDw325; Neural cadherin; N-cadherin; CD antigen CD325; CDH2; CDHN; NCAD |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human N Cadherin/CDH2 recombinant protein (Position: E170-E266). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets cadherin-2 (gene CDH2) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 99.8 kDa, and the supplier reports an observed band at about 150 kDa.
N-cadherin (CDH2) is a classical cadherin that mediates calcium-dependent adhesion in neural tissue, heart muscle, and other mesenchymal cells. It helps organize neural development and cardiac intercalated discs, and its gain during epithelial–mesenchymal transition makes it a common marker in cancer invasion studies.
| Target | Cadherin-2 (gene CDH2; UniProt P19022, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 99.8 kDa |
| Observed MW | 150 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human, Mouse, Rat) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human A549 cells, human HEK293 cells, rat liver tissue, mouse liver tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): mouse heart tissue, rat heart tissue, human liver cancer tissue, human lung cancer tissue, human pancreatic cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): human liver cancer tissue, human liver tissue, mouse heart tissue, rat heart tissue.
Samples with confirmed staining (ICC/IF): HeLa cells.
Samples with a confirmed signal (flow cytometry): HepG2 cells.
Immunogen
Recombinant human N Cadherin/CDH2 fragment (Glu170–Glu266), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places cadherin-2 in the cell membrane, cell junction, cell surface and cell projection. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Shuting Li et al. (2024) Ursolic acid, an inhibitor of TMEM16A, co-loaded with cisplatin in hydrogel drug delivery system for multi-targeted therapy of lung cancer. International Journal of Biological Macromolecules. 10.1016/j.ijbiomac.2024.134587
Yan Sun et al. (2014) MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. Journal of Pathology. 10.1002/path.4443
Xinbo Wei et al. (2023) Hepatocyte-targeted delivery using oleanolic acid-loaded liposomes for enhanced hepatocellular carcinoma therapy. Biomaterials Science. 10.1039/D3BM00261F
Shuai Guo et al. (2021) TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment. International Journal of Molecular Sciences. 10.3390/ijms222010930
Xue Bai et al. (2022) Caffeic Acid, an Active Ingredient in Coffee, Combines with DOX for Multitarget Combination Therapy of Lung Cancer. Journal of Agricultural and Food Chemistry. 10.1021/acs.jafc.2c03009
Guo Shuai et al. (2021) Inhibition of TMEM16A by Natural Product Silibinin: Potential Lead Compounds for Treatment of Lung Adenocarcinoma. Frontiers in Pharmacology. 10.3389/fphar.2021.643489
Shuning Han et al. (2024) MiR-1290 induces endothelial-to-mesenchymal transition and promotes vascular restenosis after angioplasty by targeting FGF2. Atherosclerosis. 10.1016/j.atherosclerosis.2024.118527
Tongtong Lan et al. (2025) Gut microbiota dysbiosis impairs TGF-β/Smad4 signaling to drive postoperative metastasis in colorectal cancer. Frontiers in Microbiology. 10.3389/fmicb.2025.1654227
Ying Jin et al. (2026) SMURF1 Regulates CTCF-HOXA10 Axis and Promotes Tumor Progression in Nasopharyngeal Carcinoma. Cancer Science. 10.1111/cas.70353
ZiQian Liu et al. (2026) YTHDF3 Mediates the Occurrence and Development of Breast Cancer by Regulating Glycolysis Through the mTOR–HIF1α–LHDA Axis. Journal of Cellular and Molecular Medicine. 10.1111/jcmm.71105
